文献速递乳房整形与再造

两阶段胸肌前乳房重建:应用与不应用脱细胞真皮基质的整群随机非劣效试验

Two-Stage Prepectoral Breast Reconstruction with and without Acellular Dermal Matrix: A Cluster-Randomized Noninferiority Trial.
PubMed 文献 · Plast Reconstr Surg · 2026-03-11

该单中心整群随机非劣效试验纳入368例患者(623侧乳房)行两阶段胸肌前乳房重建,比较应用与不应用脱细胞真皮基质(ADM)的主要并发症。结果显示两组90天内主要并发症发生率相似(ADM组13.2% vs 无ADM组13.1%),单侧95%CI上限低于预设7%界值,证实非劣效;次要结局包括轻微并发症、BREAST-Q评分及疼痛两组相当。结论支持ADM作为安全选项常规使用,但需长期随访明确其获益。

要点

  • 两阶段胸肌前重建中,ADM组90天主要并发症非劣效于无ADM组。
  • 轻微并发症、BREAST-Q评分及疼痛两组无显著差异。
  • 结论支持ADM常规使用,但长期获益尚待随访明确。

核心结论

  • 两阶段胸肌前乳房重建中,应用ADM在90天主要术后并发症方面非劣效于不应用ADM。

研究设计与样本

  • 单中心、整群随机非劣效试验,纳入368例患者(623侧乳房)行两阶段胸肌前乳房重建,随机分入ADM组或无ADM组。

主要发现

  • 主要并发症发生率ADM组13.2%、无ADM组13.1%,单侧95%CI上限低于7%界值,证实非劣效。
  • 轻微并发症如血清肿ADM组20%、无ADM组27.4%(p=0.056),无显著差异。
  • BREAST-Q评分在30天(ADM组60、无ADM组55;p=0.2)和90天(两组均为76;p=0.3)相当。
  • 术后疼痛两组相似。

关键数值与推荐

  • 非劣效界值定义为主要并发症率差值(ADM减无ADM)的单侧95%CI上限小于预设7%。
  • 主要终点为90天内至少发生一种主要并发症(感染、再手术或取出假体)的乳房比例。

临床怎么用

  • 支持在两阶段胸肌前乳房重建中将ADM作为安全选项常规使用。
  • 需长期随访比较相关临床结局以明确ADM的获益。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acellular dermal matrix (ADM) is frequently used in two-stage prepectoral breast reconstruction; however, concerns persist regarding increased infection rates with its use and overall benefits. This randomized controlled trial evaluated whether ADM in prepectoral reconstruction is noninferior to the alternative of no ADM with regard to major postoperative complications. METHODS: In this single-center, cluster-randomized noninferiority trial, 368 patients (623 breasts) undergoing two-stage prepectoral reconstruction were assigned to ADM or no ADM groups. The primary endpoint was the proportion of breasts with at least one major complication (infection, reoperation, or explantation) within 90 days. Noninferiority was defined as the upper bound of the one-sided 95% confidence interval (CI) for the difference in complication rates (with ADM minus no ADM) being less than the pre-specified margin of 7%. Secondary outcomes included minor complications, BREAST-Q scores, and pain. RESULTS: Major complications were similar between groups (ADM: 13.2% vs. no ADM: 13.1%; one-sided 95% CI upper bound below 7%), confirming noninferiority. Minor complications, including seroma (ADM: 20%, no ADM: 27.4%; p=0.056) showed no significant difference. BREAST-Q scores were comparable at 30 (ADM: 60, no ADM: 55; p=0.2) and 90 days (76 in both groups; p=0.3). Postoperative pain was similar between groups. CONCLUSION: Two-stage prepectoral breast reconstruction with ADM was noninferior to reconstruction without ADM regarding major 90-day postoperative complications, with comparable minor complications, patient-reported outcomes, and pain. These findings support the routine use of ADM as a safe option. Long-term follow-up comparing relevant clinical outcomes is needed to clarify the benefits of ADM.Trial Registration: Clinicaltrials.gov NCT05316324.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Nelson JA, Shammas RL, Boe LA, et al. Two-Stage Prepectoral Breast Reconstruction with and without Acellular Dermal Matrix: A Cluster-Randomized Noninferiority Trial. Plast Reconstr Surg. 2026. PMID: 41811168. doi:10.1097/PRS.0000000000013019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。